GET THE APP

Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab
Journal of Perioperative Medicine

Journal of Perioperative Medicine
Open Access

ISSN: 2684-1290

+44 20 3868 9735

Short Communication - (2020)Volume 3, Issue 3

Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab

A Papadopoulou
 

Author info »

Abstract

Bullous pemphigoid (BP) is an acquired autoimmune blistering disease affecting especially the elderly. Among drugs implicated in BP pathogenesis, anti TNFa agents have been reported as inducing agents. Ustekinumab is a monoclonal antibody that targets the IL-12/23 receptor and is approved for treating moderate to severe psoriasis. Coexistence of BP and psoriasis represents a therapeutic challenge. We report a 52 year old male patient with psoriasis who developed BP after treated with adalimumab. Long term remission of both cutaneous diseases was achieved after administration of ustekinumab. In our knowledge, this is the second case of completely resolution of BP and psoriasis with monoclonal IL-12/23 agent.

Biography

A Papadopoulou is undertaking a PhD with the title â??Assessing the value of community arts-based public health interventions for use in economic evaluationâ? under the supervision of Prof. Helen Mason (DoS) and Prof. Gianna Cassidy. Her research study is mainly focused on valuing and refining outcome measures for economic evaluations in health by using a mixed-method approach. Current research project includes the evaluation of organized street music events in New York City (Sing for Hope).

Journal-Perioperative-Medicine title=

Author Info

A Papadopoulou
 
University of Thessaly, Greece
 

Citation: A Papadopoulou, Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab, Dermatology Congress 2020, 5th International Conference on Dermatology and Trichology, July 22, 2020, 02.

Received: 10-Jun-2020 Accepted: 24-Jun-2020 Published: 18-Sep-2020 , DOI: 10.35248/2684-1290.20.3.110

Copyright: -

Sources of funding : -